DOCSLIB.ORG

DDM 4 Case 2 Group 8

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DDM 4 Case 2 Group 8 DDM 4 Case 2 Group 8 Calei Ca Angela Berry Diandra Alston Baele Dumas Alina Forshee Nia Haley Xandria Milligan Collect CC: Confusion ​ HPI: 67-year-old AA female with PMH of DM2, HTN, and Stage 5 CKD, ​ receiving HD TIW. Brought to ED this morning by her husband, who reports increased confusion and lethargy, worsening over the past 2-3 days. According to her husband, the patient missed HD session 2 days ago. He reports no other new Sx except for increased pain in her feet from neuropathy, for which PCP increased her gabapentin dose last week. PMH: Patient was diagnosed with type 2 diabetes in 1997 and hypertension in ​ 1987. Patient was diagnosed with stage 5 chronic kidney disease in 2012 and placed on hemodialysis with no residual renal function. Patient has also been diagnosed with diaetic neuropathy in 2007, anemia of chronic kidney disease in 2010, dyslipidemia in 1992, and chronic kidney disease mineral and bone disorder in 2012. Allergies: No known allergies. ​ FH: Father was diagnosed with coronary artery disease and is now deceased. ​ Mother was diagnosed with diabetes mellitus and hypertension and is now deceased. Relevant SH: Patient is married and lives with her husband. Patient is retired and ​ is on disability pay. Patient is a former smoker, quit in 2014, and quit drinking in 2010. ROS: (+) Increased fatigue and confusion; (+) reduced sensation in LE ​ Lab Test Results: Lab values show that this patient's BUN is high, potassium level is high, bicarbonate level is low, creatinine level is very high, glucose level is high, hemoglobin level is low, hematocrit level is slightly low, albumin level is low, phosphate level is high, parathyroid hormone level is very high, and EKG showed peaked T waves. All other tested values were normal. ​ BUN: 82 K+: 6.1 HCO₃-: 18 Cr: 8.2 Glucose: 118 Hgb: 11.2 Hct: 34.5% Albunimum: 2.2 Phosphate: 7.4 PTHi: 140 pg/mL ABG: HCO₃-: 20 EKG: peaked T-waves in lead V3 All other lab values are within normal range. Physical Exam Findings: General: Somnolent; appears to be in NAD Vital Signs: BP 168/82 mm Hg, P 82 bpm, RR 14, T 36.8°C; dry body Wt 68 kg, Ht 5′5″ HEENT: normal Neck/Lymph Nodes: Positive JVD Lungs: Crackles in bases BL CV: RRR MS/Ext: 1+ BL pedal edema Neuro: A & O to person only; CN II–XII intact; DTRs 2+ BL Current Medications: · Calcium acetate 667 mg, 2 PO TID ​ ​ · Gabapentin 300 mg PO BID (increased last week from 300 mg PO HS) ​ ​ · Nephrocaps 1 PO daily ​ ​ · Metoprolol tartate 25 mg PO BID ​ ​ · Amlodipine 10 mg PO daily ​ ​ · Simvastatin 40 mg PO daily ​ ​ · Glipizide XL 10 mg PO daily ​ ​ · Sitagliptin 25 mg PO daily ​ ​ · Ensure Original Vanilla nutritional supplement 237 mL PO TID ​ ​ Current Medications (verified per Outpatient Dialysis): ● Sodium ferric gluconate 62.5 mg IV once weekly with HD ● Epogen® 6000 IU IV TIW with HD ● Calcijex® 2 mcg IV TIW with HD Assess 1. Non-compliance on Hemodialysis for CKD 2. Diabetic Neuropathy 2. Hypertension 3. Anemia 4. Vaccines Plan 1. Complete hemodialysis as schedules (CrCl is 6 mL/min) ​ ​ a. Initiate Kionex immediately b. D/C Ensure since very high in protein and recommend low protein diet 2. Decrease patient’s pain and increase her quality of life. ​ ​ a. D/C Gabapentin and initiate lidocaine 5% 2. Target BP < 140/90 (Based on JNC-8 Guidelines) ​ ​ a. Prevent cardiovascular events or end-organ damage b. Reduce hypertension-related mortality c. D/C Metoprolol and initiate Lisinopril once hyperkalemia is treated d. D/C Simvastatin and initiate Rosuvastatin due to Amlodipine having interactions with Simvastatin 3. Increase hemoglobin level to target 12-15.5 g/dL ​ ​ 4. Vaccines ​ ​ a. Ensure patient is up to date on vaccinations to prevent risk of infections, morbidity and mortality 1. The patient must complete Hemodialysis as scheduled (TIW) a. Educate the patient on the importance and benefits of hemodialysis compliance. b. Find out the underlying cause as to why the patient did not attend their last hemodialysis session. c. Initiate Kionex 15 g (60 mL) of one to four times daily. Take the medication 3 hours before or three hours after oral medications. d. Recommend low protein diet [0.6 to 0.75 grams of protein per kilogram body weight] 2. Initiate Lidocaine 5%. Apply one patch to foot every 12 hours as needed for pain. Administer cautiously since patient has stage 5 CKD 2. Initiate Lisinopril 20 mg daily once hyperkalemia is treated Initiate Rosuvastatin 10 mg daily and discontinue Simvastatin due to interactions between Amlodipine and Simvastatin. 3. Increase sodium ferric gluconate to 100 mg/week to improve response to ESA therapy a. Educate the patient on increasing dietary intake of iron-rich food 4. Flu vaccine once per year Pneumovax 23 (Pneumococcal Polysaccharide 23-valent) vaccine give first if not given already, then give prevnar13 a year later Hepatitis B vaccination if not given already Follow-up: 1. Ensure patient is compliant on hemodialysis schedule ​ ​ Monitor a. Make sure patient adheres to hemodialysis schedule and and ​ ​ Evaluate stays on the full regimen (goes three times per week) b. Monitor patient’s BUN, Scr, serum electrolytes, and ​ ​ hemoglobin and hematocrit levels before and after dialysis c. Monitor patient’s potassium level until back to normal range ​ ​ (3.5-5 mEq/mL) d. Make sure patient is adherent to low protein diet 2. Monitor application area for burning, discomfort, redness or ​ ​ swelling, as Lidocaine can cause these side effects. Also, monitor for lightheadedness or dizziness 2. Ensure compliance with Lisinopril ​ ​ a. Monitor BP every visit to hemodialysis ​ ​ b. Monitor anaphylactic reactions ​ ​ c. Monitor swelling of the hands, face, mouth, or throat ​ ​ Ensure compliance with Rosuvastatin a. Monitor LFT’s and for rhabdomyolysis 3. Monitor hgb and hct twice weekly, then monthly ​ ​ a. Monitor hgb and hematocrit for efficacy ​ ​ 4. Efficacy: ​ Immunity to the influenza virus, hepatitis B virus, and Pneumococcal infections. Safety: ● Hypersensitivity reactions ● Injection site reactions ● Fever ● Muscle ache References Carter, Barry L, James, Paul A, Oparil, Suzanne. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507-520. doi: 10.1001/jama.2013.284427. Cassagnol, M, Harisingani, R, Sadd, M. How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis? The Hospitalist. 2013(8). DailyMed - KIONEX- sodium polystyrene sulfonate suspension. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed November 10, 2019 Lidoderm (Lidocaine Patch 5%): Side Effects, Interactions, Warning, Dosage & Uses. RxList. https://www.rxlist.com/lidoderm-drug.htm#description. Published October 25, 2018. Accessed November 11, 2019. Ldsay, TJ, Snyder, MJ. Treating Painful Diabetic Peripheral Neuropathy: An Update. American Family ​ Physician. 2016 Aug 1;94(3):227-234. https://www.ncbi.nlm.nih.gov/pubmed/27479625. ​ ​ ​ Reference Ranges. American College of Physicians. https://annualmeeting.acponline.org/educational-program/handouts/reference-ranges-table. Accessed October 5, 2019. Overview and Discussion of Chronic Kidney Disease (CKD) Epidemiology of theDisease · CKD is defined as abnormalities of kidney structure or function, present for greater than 3 months, with implications for health. CKD is recognized as a significant health problem associated with: o High morbidity and mortality § Each year, kidney disease kills more people than breast or prostate cancer. In 2013, more than 47,000 Americans died from kidney disease. § Hospitalization rates decreased by 11 percent for CKD patients and by 10.1 percent for those without CKD. However, rates of both overall and cause-specific admissions increased with advancing stages of CKD. § In 2013, adjusted mortality rates remained higher for Medicare patients with CKD (117.9/1,000) than for those without CKD (47.5/1,000); and these rates increased with CKD severity. o High economic burden to health care systems. · Prevalence of CKD o The overall prevalence of CKD increased from 12 percent to 14 percent between 1988 and 1994 and from 1999 to 2004 but has remained relatively stable since 2004. o Women (15.93 percent) are more likely to have stages 1 to 4 CKD than men (13.52 percent). o African Americans (17.01 percent) and Mexican Americans (15.29 percent) are more likely to have CKD than Caucasians (13.99 percent). · Complications o Fluid retention o Hyperkalemia, which could impair your heart's ability to function and may be life-threatening o Cardiovascular disease o Weak bones and an increased risk of bone fractures o Anemia o Erectile dysfunction o Damage to your central nervous system o Decreased immune response o Pregnancy complications that carry risks for the mother and the developing fetus o End stage renal disease, eventually requiring either dialysis or a kidney transplant for survival Etiology · Clinical factors o Type 1 and 2 diabetes o High blood pressure o Glomerulonephritis o Polycystic kidney disease o Prolonged obstruction of the urinary tract, such as enlarged prostate or kidney stones o Vesicoureteral reflux o Pyelonephritis · Socioeconomic factors o Older age o US ethnic minority status o Exposure to certain chemicals and environmental conditions o Low income/education · Classification o Stage 1 CKD: >90 mL/min/1.73 m3 – Normal or high o Stage 2 CKD: 60-89 mL/min/1.73 m3 – Mildly decreased o Stage 3a CKD:49-59 mL/min/1.73 m3 – Mildly to moderately decreased o Stage 3b CKD: 30-44 mL/min/1.73 m3 – Moderately to severely
Load more

Recommended publications
  • How to Take Your Phosphate Binders
    How to take your phosphate binders Information for renal patients Oxford Kidney Unit Page 2 What are phosphate binders? To reduce the amount of phosphate you absorb from your food you may have been prescribed a medicine called a phosphate binder. Phosphate binders work by binding (attaching) to some of the phosphate in food. This will reduce the amount of phosphate being absorbed into your blood stream. A list of phosphate binders and how to take them is shown below. Phosphate binder How to take it Calcichew (calcium carbonate) Chew thoroughly 10-15 minutes before or immediately before food Renacet (calcium acetate) Phosex (calcium acetate) Osvaren (calcium acetate and magnesium carbonate) Swallow whole after the first Renagel 2-3 mouthfuls of food (sevelemer hydrochloride) Renvela tablets (sevelemer carbonate) Alucaps (aluminium hydroxide) Renvela powder Dissolve in 60ml of water and (sevelemer carbonate) take after the first 2-3 mouthfuls of food Fosrenol tablets Chew thoroughly towards the (lanthanum carbonate) end/immediately after each meal Fosrenol powder Mix with a small amount of (lanthanum carbonate) food and eat immediately Velphoro Chew thoroughly after the first (sucroferric oxyhydroxide) 2-3 mouthfuls The phosphate binder you have been prescribed is: ……………………………………………………………………………………………………………………………………………………….. Page 3 How many phosphate binders should I take? You should follow the dose that has been prescribed for you. Your renal dietitian can advise how best to match your phosphate binders to your meal pattern, as well as which snacks require a phosphate binder. What happens if I forget to take my phosphate binder? For best results, phosphate binders should be taken as instructed.
    [Show full text]
  • New Brunswick Drug Plans Formulary
    New Brunswick Drug Plans Formulary August 2019 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick TABLE OF CONTENTS Page Introduction.............................................................................................................................................I New Brunswick Drug Plans....................................................................................................................II Exclusions............................................................................................................................................IV Legend..................................................................................................................................................V Anatomical Therapeutic Chemical (ATC) Classification of Drugs A Alimentary Tract and Metabolism 1 B Blood and Blood Forming Organs 23 C Cardiovascular System 31 D Dermatologicals 81 G Genito Urinary System and Sex Hormones 89 H Systemic Hormonal Preparations excluding Sex Hormones 100 J Antiinfectives for Systemic Use 107 L Antineoplastic and Immunomodulating Agents 129 M Musculo-Skeletal System 147 N Nervous System 156 P Antiparasitic Products, Insecticides and Repellants 223 R Respiratory System 225 S Sensory Organs 234 V Various 240 Appendices I-A Abbreviations of Dosage forms.....................................................................A - 1 I-B Abbreviations of Routes................................................................................A - 4 I-C Abbreviations of Units...................................................................................A
    [Show full text]
  • Evaluation of Single Dose Sodium Polystyrene
    Open Access Original Article Sodium Polystyrene Sulfonate For Management of Hyperkalemia Pak Armed Forces Med J 2019; 69 (1): 37-42 EVALUATION OF SINGLE DOSE SODIUM POLYSTYRENE SULFONATE FOR MANAGEMENT OF HYPERKALEMIA AND ITS EFFECT ON OTHER SERUM ELECTROLYTES Shoaib Alam, Azfar Athar Ishaqui, Masood Ahmed Khan, Adnan Iqbal, Syed Hameez Jawed, Farah Khalid, Mir Muhammad Uzairullah, Muhammad Talha*, Usman Ashfaq*, Najam Zehra* University of Karachi, Karachi Pakistan, *Hamdard University Karachi Pakistan ABSTRACT Objective: To assess the effectiveness of sodium polystyrene sulphonate in treating hyperkalemia and its effect on different serum electrolytes level. Study Design: Quasi-experimental study. Place and Duration of Study: Lyari general hospital, 500 bedded tertiary care public sector hospital at Karachi, from Jan 2017 to Mar 2017. Material and Methods: Hyperkalemic patients were included in study who fulfilled inclusion criteria and were administered with single STAT 30 grams dose of Sodium Polystyrene Sulfonate. Serum electrolytes such as sodium, chloride, magnesium, phosphate and calcium were measured before and after 2 hours of administration of Sodium Polystyrene Sulfonate. Paired t-test was used as tool for statistical analysis. Results: Significant (p<0.05) decrease in serum potassium level with mean decrease of 0.61 mmol/L was observed in hyperkalemic patients (n=83) after single dose of Sodium Polystyrene Sulfonate. Among 83 studied patient, 67 (81%) recovered from hyperkalemia. Besides, there was significant (p<0.05) increase in sodium level with a mean increase of 2.26 mmol/L. Serum magnesium and calcium levels were significantly decreased (p<0.05) with mean difference of 0.02mmol/L and 0.13mmol/L respectively.
    [Show full text]
  • In-Class Targeted Therapies That Advance Patient Care
    Passionately committed to improving the lives of patients by discovering, developing and commercializing first- in-class targeted therapies that advance patient care November 2020 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including statements regarding the potential for Ardelyx’s product candidates in treating the diseases and conditions for which they are being developed; Ardelyx’s expectation regarding the potential approval of its NDA for tenapanor for the control of serum phosphorus in chronic kidney disease (CKD) patients on dialysis and the expected timing thereof; the commercial potential for tenapanor for the control of serum phosphorus in CKD patients on dialysis, including Ardelyx’s expectation regarding the rate of adoption and use of tenapanor, if approved; Ardelyx’s expectations regarding the size of the patient population and the size of the market for tenapanor in CKD patients on dialysis, and the potential growth thereof; and Ardelyx’s expectations regarding the exhaustion of its current capital resources. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of Ardelyx’s product candidates or Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in research and the clinical development process; the uncertainties associated with the regulatory approval process; and the uncertainties in the drug commercialization process.
    [Show full text]
  • Phosphate Binders
    Pharmacy Info Sheet Phosphate Binders calcium acetate, calcium carbonate (Tums, Calsan, Apocal, Ocal), calcium liquid, aluminum hydroxide (Basaljel, Amphojel), sevelamer (Renagel), lanthanum (Fosrenol) What it does: Phosphate binders are used to treat high Special considerations for lanthamum and blood phosphorus levels. sevelamer: Calcium acetate, calcium carbonate, calcium Lanthanum should be taken during or liquid, aluminum hydroxide, lanthanum and immediately after a meal. Taking a dose on an sevelamer bind dietary phosphate. When the empty stomach can cause nausea and kidneys fail, phosphorus builds up in the body vomiting. Chew the tablet completely before because the kidneys can no longer remove swallowing. DO NOT swallow tablets whole. much phosphorus. Phosphate binders are used to lower the amount of phosphorus Sevelamer should be taken just before eating. absorbed from food to limit development of Swallow the tablet whole – Renagel should not bone and blood vessel disease. be cut or chewed. The contents of sevelamer tablets expand in water and could cause Aluminum hydroxide and calcium carbonate choking if cut chewed or crushed. may also be prescribed as antacids. Calcium preparations may also be prescribed as Phosphate binders may interfere with the calcium supplements. Use them only as absorption of certain drugs such as iron prescribed. When these medications are supplements, antibiotics, digoxin, ranitidine, prescribed as calcium supplements or antiseizure, and antiarrhythmic medications. antacids, take between meals. If you are prescribed any of these drugs, take them at least 1 hour before or 3 hours after your How it works: phosphate binder. Kidney disease can cause phosphate to accumulate which results in bone and blood What to do if you miss a dose: vessel disease.
    [Show full text]
  • SODIUM POLYSTYRENE SULFONATE, USP Cation-Exchange Resin
    Kayexalate® SODIUM POLYSTYRENE SULFONATE, USP Cation-Exchange Resin DESCRIPTION Kayexalate, brand of sodium polystyrene sulfonate is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula: The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or in an enema. CLINICAL PHARMACOLOGY As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. For the most part, this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. It commonly approximates the order of 33 percent but the range is so large that definitive indices of electrolyte balance must be clearly monitored. Metabolic data are unavailable. INDICATION AND USAGE Kayexalate is indicated for the treatment of hyperkalemia. CONTRAINDICATIONS Kayexalate is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see PRECAUTIONS). WARNINGS Intestinal Necrosis: Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Kayexalate use.
    [Show full text]
  • Dorset Medicines Advisory Group
    Dorset Medicines Advisory Group SHARED CARE GUIDELINE FOR THE USE OF PHOSPHATE BINDERS IN THE MANAGEMENT OF HYPERPHOSPHATAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE. INDICATION This document provides guidance for the prescribing of phosphate binders for the management of hyperphosphatemia in patients receiving haemodialysis or peritoneal dialysis and patients with chronic kidney disease stage 4 or 5 who are not receiving dialysis. This shared care guideline covers adult patients under the care of the Dorset Renal Unit. Patients with chronic renal failure have reduced ability to excrete phosphate. Phosphate accumulation enhances parathyroid activity and leads to the calcification of arteries, significantly contributing to the excess cardiovascular morbidity in these patients, especially in younger age groups. Adequate control of serum phosphate levels is thought to be beneficial for the prevention of vascular and cardiac calcification in patients with renal failure and control of parathyroid hormone. A number of oral phosphate binders are available which may be used in the context of a multiple therapeutic approach. These include calcium acetate, calcium carbonate, calcium acetate/magnesium carbonate, lanthanum, sevelamer and sucroferric oxyhydroxide. These products may be used in combination with 1-hydroxycholecalciferol (alfacalcidol) or one of its analogues and/or cinacalcet to control the development of secondary hyperparathyroidism and renal bone disease. A calcium-based phosphate binder is generally used as the initial phosphate binder therapy for the treatment for hyperphosphatemia. Calcium acetate is preferred over calcium carbonate due to its lower elemental calcium content for the equivalent phosphate binding capacity, however patient preference in formulation should be taken into consideration. A non-calcium-based phosphate binder should be used in patients who cannot tolerate a calcium-based phosphate binder, whose serum calcium exceeds 2.5mmol/L or whose parathyroid levels are less than 15pmol/L.
    [Show full text]
  • AMBERLITE™ IRP69 Ion Exchange Resin Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP)
    Product Data Sheet AMBERLITE™ IRP69 Ion Exchange Resin Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP) Description AMBERLITE™ IRP69[1] resin is an insoluble, strongly acidic, sodium form cation exchange resin supplied as a dry, fine powder. AMBERLITE™ IRP69 Resin is suitable for use in pharmaceutical applications, both as an active ingredient and as a carrier for basic (cationic) drugs. It can be used for sustained release applications with compatible coating technologies. [1] The use of AMBERLITE™ pharmaceutical grade ion exchange resins as components of drug formulations is subject to the Food, Drug, and Cosmetic Act as amended. Regulatory Status A Drug Master File for AMBERLITE™ IRP69 is maintained with the United States Food and Drug Administration. Letters of authorization granting access to the file by FDA in support of NDA and ANDA submittals will be provided upon request. Similar help can also be offered in support of the registration of formulations containing AMBERLITE™ IRP69 in many other countries world- wide. AMBERLITE™ IRP69 is manufactured in accordance with Good Manufacturing Practices (cGMP) for bulk pharmaceutical chemicals Typical Properties AMBERLITE™ IRP69 complies with the compendial specifications for Sodium Polystyrene Sulfonate USP when tested in conformance to the compendial test methods presented in current USP/NF. Physical Properties Copolymer Styrene-divinylbenzene Type Strong acid cation Functional Group Sulfonic acid Physical Form Fine powder Chemical Properties Ionic Form as Shipped Na+ Heavy metals content [1] ≤ 10 ppm Potassium exchange capacity [1] 110–135 mg/g Water content [1] 10.0% maximum Ammonia salts [1] Negative to litmus paper Sodium content [1] 9.4%–11.5% Styrene content [1] 1 ppm maximum Particle Size § > 0.150 mm 1.0% maximum > 0.075 mm 10.0–25.0% §[1] Appears in current USP/NF Page 1 of 6 Form No.
    [Show full text]
  • The Indirect Implication of SARS-Cov-2 Resulting in Kayexalate Toxicity in a Patient with Acute Kidney Injury
    CODON P U B L I C A T I O N S Journal of Renal and Hepatic Disorders CASE REPORT: NEPHROLOGY The Indirect Implication of SARS-CoV-2 Resulting in Kayexalate Toxicity in a Patient with Acute Kidney Injury Charles E Middleton, IV, MD, William Daley, MD, Neha Varshney, MD Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA Abstract The clinical features of corona virus disease 2019 (COVID-19) are variable, but the majority of patients experience mild flu-like symptoms. The cases of severe disease include complications such as progressive pneumonia, acute kidney injury (AKI), multi-organ failure, and even death. This paper explores the association between COVID-19 and its effect on multiple organ systems and how the subsequent treatment of this dis- ease can itself lead to morbidity and mortality. We present a case that emphasizes the life-threatening gastrointestinal complications associated with the treatment of AKI in a patient with COVID-19. We conclude that the patients whose treatment regimens utilize medical resins should be closely monitored for gastrointestinal complications so as to mitigate the known adverse effects associated with these drugs, such as colonic mucosal ulceration, perforation, or even death. Keywords: acute kidney injury; colonic perforation; COVID-19; Kayexalate; resins; sevelamer Received: 25 November 2020; Accepted after revision: 5 February 2021; Published: 27 February 2021. Author for correspondence: Neha Varshney, MD, Assistant Professor, Department of Pathology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4500, USA. Email: [email protected] How to cite: Middleton CE, et al.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Nephrology II BONE METABOLISM and DISEASE in CHRONIC KIDNEY DISEASE
    Nephrology II BONE METABOLISM AND DISEASE IN CHRONIC KIDNEY DISEASE Sarah R. Tomasello, Pharm.D., BCPS Reviewed by Joanna Q. Hudson, Pharm.D., BCPS; and Lisa C. Hutchison, Pharm.D., MPH, BCPS aluminum toxicity. Adynamic bone disease is referred to as Learning Objectives low turnover disease with normal mineralization. This disorder may be caused by excessive suppression of PTH 1. Analyze the alterations in phosphorus, calcium, vitamin through the use of vitamin D agents, calcimimetics, or D, and parathyroid hormone regulation that occur in phosphate binders. In addition to bone effects, alterations in patients with chronic kidney disease (CKD). calcium, phosphorus, vitamin D and PTH cause other 2. Classify the type of bone disease that occurs in patients deleterious consequences in patients with CKD. Of these, with CKD based on the evaluation of biochemical extra-skeletal calcification and increased left ventricular markers. mass have been documented and directly correlated to an 3. Construct a therapeutic plan individualized for the stage increase in cardiovascular morbidity and mortality. The goal of CKD to monitor bone metabolism and the effects of of treatment in patients with CKD and abnormalities of bone treatment. metabolism is to normalize mineral metabolism, prevent 4. Assess the role of various treatment options such as bone disease, and prevent extraskeletal manifestations of the phosphorus restriction, phosphate binders, calcium altered biochemical processes. supplements, vitamin D agents, and calcimimetics In 2003, a non-profit international organization, Kidney based on the pathophysiology of the disease state. Disease: Improving Global Outcomes, was created. Their 5. Devise a therapeutic plan for a specific patient with mission is to improve care and outcomes for patients with alterations of phosphorus, calcium, vitamin D, and CKD worldwide by promoting, coordinating, collaborating, intact parathyroid hormone concentrations.
    [Show full text]
  • Case Report Sevelamer Carbonate Crystal-Induced Colitis
    Hindawi Case Reports in Gastrointestinal Medicine Volume 2020, Article ID 4646732, 4 pages https://doi.org/10.1155/2020/4646732 Case Report Sevelamer Carbonate Crystal-Induced Colitis T. Lai ,1 A. Frugoli ,2 B. Barrows,3 and M. Salehpour4 1Community Memorial Health System, Graduate Medical Education, Ventura, CA, USA 2Community Memorial Health System, Graduate Medical Education, Department of Internal Medicine, Pacific Inpatient Physicians, Ventura, CA, USA 3Community Memorial Hospital, Department of Pathology, Ventura, CA, USA 4Community Memorial Hospital, Department of General Surgery, Ventura, CA, USA Correspondence should be addressed to T. Lai; [email protected] Received 19 February 2020; Accepted 30 March 2020; Published 24 July 2020 Academic Editor: Olga I. Giouleme Copyright © 2020 T. Lai et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hyperphosphatemia is a common and well-described complication of end-stage renal disease. Despite strict dietary constraints and compliance, phosphate binders such as calcium acetate and/or sevelamer carbonate are also needed to treat secondary hyperparathyroidism. )is case vignette describes an underrecognized adverse effect of a phosphate binder, sevelamer carbonate, inducing colitis in a 47-year-old male with insulin-dependent diabetes complicated by end-stage renal disease. He presented for recurrent abdominal pain with associated nausea and was found to have multiple circumferential lesions on computed to- mography including distal ascending, transverse, and proximal descending colon. Colonoscopy demonstrated nearly obstructing lesions worrisome for colonic ischemia or inflammatory bowel disease. Pathological review of histology demonstrated ragged colonic mucosa with ulcerative debris and nonpolarizing crystalline material at the sites of ulceration, morphologically consistent with the phosphate binder, sevelamer carbonate.
    [Show full text]